Aneta Rotterova

Aneta Rotterova

Auto-generated profile, based on publicly available information

Aneta Rotterova

University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Journal of Neurochemistry
Verified
Journal Article
Closed access
MSMonika Schmidt
Monika Schmidt
M(Michaela Hanzlová (Vašková)
Michaela Hanzlová (Vašková)
ARAneta Rotterova
Aneta Rotterova
PFPavlina Fiandova
Pavlina Fiandova
MMMarketa Miskerikova
Marketa Miskerikova
KMKamil Musilek
Kamil Musilek

25 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAneta Houfková
Aneta Houfková
MSMonika Schmidt
Monika Schmidt
OBOndrej Benek
Ondrej Benek
IFIvo Fabrik
Ivo Fabrik
RARudolf Andrýs
Rudolf Andrýs
KMKamil Musilek
Kamil Musilek
The multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD10) plays an important role in the pathology of several diseases, of which Alzheimer’s disease (AD) is the most debated. HSD10 overexpression and its interplay with amyloid-β peptide (Aβ) are considered a factor contributing to mitochondrial damage and neuronal stress observed in AD patients. This study confirms that individual overexpression of HSD10 or APP (amyloid precursor protein that gives rise to Aβ) leads to cytotoxicity, and both pathological conditions are linked to mitochondrial damage. However, the metabolic changes caused by these two overexpressions significantly differ, particularly in their effect on the tricarboxylic acid cycle and β-oxidation. Furthermore, the enzymatic activity of HSD10 is identified as the primary factor of HSD10 cytotoxicity, which is significantly exacerbated in an Aβ-rich environment and can be partially reversed by HSD10 inhibitors. Notably, a previously published and competitive benzothiazole inhibitor was effective in restoring the viability of HSD10 overexpressing cells alone and in an Aβ-rich environment, implying the potential benefit of HSD10 inhibitors in mitochondrial diseases and/or AD treatment. GRAPHICAL